Bausch Health resolves IBS patent litigation
07-05-2020
Senju, Bausch settle eye drop litigation against Indian generics maker
09-01-2020
Pavel Kapysh / Shutterstock.com
Dispute centres on Xifaxan, used to treat irritable bowel syndrome | ‘Significant hurdle’ cleared in bringing drug to market | Bausch wins partial victory after Alvogen subsidiary failed to show that patent claims were obvious.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Alvogen, Norwich Pharmaceuticals, generics, Bausch Health, Salix, patent infringement, IBS, patents
